Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyoscine + ibuprofen is a fixed-dose combination medication containing two active ingredients: - **Hyoscine butylbromide** (also known as scopolamine butylbromide), an antispasmodic and anticholinergic agent that relieves smooth muscle spasms in the gastrointestinal, biliary, and genitourinary tracts by blocking muscarinic acetylcholine receptors. - **Ibuprofen**, a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic, anti-inflammatory, and antipyretic effects primarily through inhibition of cyclooxygenase enzymes (COX-1 and COX-2), leading to reduced synthesis of prostaglandins involved in pain and inflammation. This combination is designed to provide both spasmolytic relief from smooth muscle cramps (via hyoscine) and direct pain relief/anti-inflammation (via ibuprofen). It has been developed for symptomatic treatment of conditions such as abdominal cramping, dysmenorrhea (menstrual pain), renal colic, biliary tract spasm, ureteral colic, and other types of visceral pain where both muscle spasm and inflammation contribute to symptoms. The synergistic effect aims for faster onset and greater overall symptom control compared to monotherapy with either agent[1][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyoscine + ibuprofen.